UnknownNot Applicable

Novel Biomarker Assay for Biomarker Assay for HCC Detection

200 participantsStarted 2022-12-01

Plain-language summary

The primary purpose of this study is to assess the performance feasibility of Genetron's novel HCC liquid biopsy biomarkers assay for early detection. Piedmont Transplant Institute will provide a longitudinally collected blood sample from all HCC cases (mixture of early and advanced stage HCC) and cirrhosis control to Genetron Health after obtaining informed consent.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with HCC (based on histology or radiology according to AASLD guideline) or liver cirrhosis (based on the clinical history of hepatic encephalopathy, thrombocytopenia, radiologic features of the nodular liver, features of portal hypertension such as ascites, splenomegaly, or MR elastogram or fibroscan showing result consistent with cirrhosis) * Willing and able to provide informed consent to participate in this study Exclusion Criteria: * Unable to provide blood samples * Age less than 18 years of age * Patient who have active cancers (excluding HCC) in the past five years, except for nonmelanoma skin cancer

What they're measuring

HCC screening positive

Timeframe: 2 years

Trial details

NCT IDNCT05494853

SponsorGenetron Health

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-12-01

Contact for this trial

Moin Ahmad

12403506177 mahmad@genetronhealth.us

View on ClinicalTrials.gov More Hepato-cellular Carcinoma trials